anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is a randomized (study medication assigned to participants by chance), single-center, parallel-group single-application, modified 3-way crossover study. Each participant will receive the marketed reference formulation (DURAGESIC) or the JNJ-35685-AAA-G016 or JNJ-35685-AAA-G021 fentanyl transdermal system (TDS). The study consists of a screening phase within 21 and 2 days before the first TDS application of the first period; a partially-blinded treatment phase consisting of 3 single-application treatment periods; and end-of-study or withdrawal assessments done upon completion of the 72-hour adhesion assessment on Day 5 of Period 3 or upon withdrawal. A 7- to 16-day washout period will separate the treatment periods, commencing at transdermal patch removal. The duration of participation in the study for an individual participant will be 31 days to a maximum of 68 days (including screening and follow-up visits). Participants will be primarily evaluated for cumulative adhesion percentage. Participants' safety will be monitored throughout the study.
PURPOSE:To obtain a tumoricidal substance from supernatant liquid obtained by culturing a macrophage originated from mammals in a medium containing a composite protein originated from Sarcophaga peregrina and having lectin-like activity. CONSTITUTION:A composite protein exhibiting lectin-like activity and having a molecular weight of about 188,000 by gel-filtration and consisting of 4 subunits having a molecular weight of about 32,000 by SDS-gel electrophoresis and 2 subunits having a molecular weight of about 30,000 is prepared by pricking the body surface of a maggot or chrysalis of the early pupal stage of Sarcophaga peregrina, homogenizing the body for several minutes with a blender, and extracting, purifying and separating the objective substance. The composite protein is added to a medium for animal cell at a concentration of 1-100mug/ml, and a mammal- originated macrophage (e.g. mouse-originated monocytic leukemia cell strain J-774) is cultured in the medium. The objective tumoricidal substance which is a proteinous substance having a molecular weight of about 30,000-70,000 is separated from the supernatant liquid of the culture medium. The substance loses its activity by heating at 90 deg.C for 30min and loses about 20% of the activity at 56 deg.C for 30min.
BACKGROUND/AIMS: Longitudinal studies assessing the impact of genetic polymorphisms on outcomes in patients with Type 2 Diabetes Mellitus (T2DM) and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) are scarce. This study aimed to evaluate the effect of PNPLA3 and TM6SF2 risk alleles on hepatic and extrahepatic outcomes in T2DM-MASLD individuals.
METHODS: Patients' polymorphisms were analysed as follows: PNPLA3 CC, CG and GG; TM6SF2 CC and CT + TT; combined comparing no mutant allele, one allele G or T or ≥2 alleles G or T. Hierarchical models were built to assess associations between polymorphisms and outcomes, independently of confounding factors. Multivariate logistic regression was used for cirrhosis and its complications and extrahepatic cancer, and Cox regression for cardiovascular events (CVEs) and all-cause mortality.
RESULTS: In total, 407 T2DM-MASLD patients (62.1 ± 10.5 years, 67.6% women) were followed for 11 (6-13) years. Having at least one G or T allele independently increased the risk of cirrhosis in the separate analysis of PNPLA3 and TM6SF2. Combined polymorphism analysis demonstrated an even higher risk of cirrhosis if two or more risk alleles were present (OR 18.48; 95% CI 6.15-55.58; p < .001). Regarding cirrhosis complications, the risk was higher in PNPLA3 GG and TM6SF2 CT + TT, also with an even higher risk when two or more risk alleles were present in the combined evaluation (OR 27.20; 95% CI 5.26-140.62; p < .001). There were no associations with CVEs or mortality outcomes.
CONCLUSION: In T2DM, PNPLA3 and TM6SF2 polymorphisms, individually and additively, impact MASLD severity, with an increased risk of cirrhosis and its complications.
Patients complete quality of life questionnaires over 20 minutes at baseline (before any therapy), 2-4 and 5-9 months after completion of therapy, and then annually for up to 5 years. Patients' medical records are also reviewed.
Rotavirus (RV) NSP2 is a multifunctional RNA chaperone that exhibits numerous activities that are essential for replication and viral genome packaging. We performed an in silico analysis that highlighted a distant relationship of NSP2 from rotavirus B (RVB) to proteins from other human RVs. We solved a cryo-electron microscopy structure of RVB NSP2 that shows structural differences with corresponding proteins from other human RVs. Based on the structure, we identified amino acid residues that are involved in RNA interactions. Anisotropy titration experiments showed that these residues are important for nucleic acid binding. We also identified structural motifs that are conserved in all RV species. Collectively, our data complete the structural characterization of rotaviral NSP2 protein and demonstrate its structural diversity among RV species.IMPORTANCERotavirus B (RVB), also known as adult diarrhea rotavirus, has caused epidemics of severe diarrhea in China, India, and Bangladesh. Thousands of people are infected in a single RVB epidemic. However, information on this group of rotaviruses remains limited. As NSP2 is an essential protein in the viral life cycle, including its role in the formation of replication factories, it may be a target for future antiviral strategy against viruses with similar mechanisms.
BMI \<24kg/m2. No systemic disease, including hypertension, diabetes, liver cirrhosis, chronic kidney disease, and psychiatric disease.
Allo MUD \& MM = Allogeneic Stem Cell Transplantation, Matched unrelated donor or mismatched sibling donor transplantations: Cyclophosphamide 1000 mg/m\^2 given intravenously on Day -3, 4 hours after completion of Fludarabine 30 mg/m\^2 given intravenously on Days -5 and -3 before transplantation. Rituximab 375 mg/m\^2 given intravenously on Days -8, -1 before transplantation and Days 6, 13 after transplantation. Alemtuzumab 15 mg per day given intravenously days 1 through 3 after transplantation.
PROBLEM TO BE SOLVED: To obtain a fine granule of ethyl loflazepate capable of controlling elution, containing ethyl loflazepate and a lubricant. SOLUTION: Ethyl loflazepate is mixed with a lubricant (e.g. magnesium. stearate) in one particle and granulated. If required, ethyl loflazepate is mixed with the lubricant, an excipient, a binder, etc., and then water and granulated by a stirring granulator. Then the granule is arranged in size, dried and sieved to give a fine granule. Or the lubricant is divided into two parts, one part is mixed with ethyl loflazepate, optionally the excipient and the binder, granulated similarly to the above-mentioned method and the surface of the prepared fine granule is stuck with the remaining lubricant to give the objective substance having slightly controlled elution rate. Or the lubricant is divided into two parts, one part is mixed with ethyl loflazepate, then the excipient, the binder, etc., granulated similarly to the abovementioned method.  The surface of the prepared fine granule is stuck with the remaining lubricant to give the objective substance having a middle elution rate. The objective substance having any of various elution patters is obtained by a blending method in granulation.
INTRODUCTION: Adjustable gastric banding (AGB) used to be a popular bariatric procedure. However, it fails in more than half of those operated on in the long term, becomes ineffective and must be removed. Therefore, the use of AGB has been in decline globally. Sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB) are the most used bariatric revision surgeries when AGB is removed.
CASE REPORT: We present the case of a woman after AGB removal and conversion to SG who developed a stenosis of the sleeve. Therefore, a decision was made to convert to RYGB with a good effect.
CONCLUSION: Revisional procedures are more technically challenging than primary procedures and have higher complication rates. The most performed revisional operations include SG and RYGB. Stenosis of the sleeve can occur after SG, with a negative impact on the patient's nutritional status and quality of life. This can be managed by endoscopic dilatation, and where this solution proves ineffective, RYGB can be indicated.
The invention concerns a new lipoteichoic acid which can be isolated from the new Streptococcus sp DSM 8747. The new LTA is called LTA-T. It has a lipid anchor, which is a galacto-furanosyl-beta-1-3-glycerol with different rests of fatty acids esterified in the two adjacent hydroxy groups in the glycerol moiety and a non-glycosylated, linear, unbranched GroP chain with an unusual short hydrophilic GroP chain. The hydrophilic backbone consists of only 10 glycerophosphate units esterified with D-alanine in an extent of 30%. The invention further concerns a pharmaceutical composition with the new LTA-T, optionally together with a monokine and/or hyaluronidase, a method of treating cancer comprising administration of an antitumor effective amount thereof, a method of producing the new compound and the new pharmaceutical composition, two degradation products of the new LTA-T and their use, and the new Streptococcus strain from which the new compound can be isolated.A new bacteria species within the genus Streptococcus is disclosed, designated as Streptococcus sp PT DSM 8747. From this bacteria species a lipoteichoic acid LTA can be isolated which has a lipid anchor, galacto-furanosyl-beta-1-3-glycerol with different rests of fatty acids esterified to the two adjacent hydroxy groups in the glycerol moiety and a non-glycosylated, linear, unbranched GroP chain. The hydrophilic backbone may comprise 10 glycerophosphate units esterified with D-alanine in an extent of about 30%. The invention further concerns a pharmaceutical composition with the LTA, optionally together with a monokine and/or hyaluronidase, a method of treating cancer comprising administrating an antitumor effective amount thereof, a method of producing the LTA, and degradation products of the LTA and their use.
The subjects will wear the ITE devices in a field test for 10 +/-7 days. At the second and third visits they will perform speech testing in the lab in three randomized conditions (unaided, aided with ITE, and aided with BTE).
Metoprolol succinate is a beta1-selective (cardioselective) adrenoceptor blocking agent, for oral administration, available as extended-release tablets. Metoprolol succinate extended-release tablets have been formulated to provide a controlled and predictable release of metoprolol for once daily oral administration. The tablets comprise a multiple unit system containing metoprolol succinate in a multitude of controlled-release pellets. Each pellet acts as a separate drug delivery unit and is designed to deliver metoprolol continuously over the dosage interval. The tablets contain 47.5 mg of metoprolol succinate equivalent to 50 mg of metoprolol tartrate, USP. Its chemical name is (±) 1-(isopropylamino)-3-[p-(2-methoxyethyl) phenoxy]-2-propanol succinate (2:1) (salt). Its structural formula is: 

Metoprolol succinate is a white crystalline powder with a molecular weight of 652.8. It is freely soluble in water; soluble in methanol; sparingly soluble in ethanol; slightly soluble in dichloromethane and 2-propanol; practically insoluble in ethyl-acetate, acetone, diethylether and heptane. Inactive ingredients: calcium stearate, carboxymethylcellulose sodium, carnauba wax, croscarmellose sodium, glyceryl behenate, hydrogenated vegetable oil, hypromellose, maltodextrin, methacrylic acid copolymer, microcrystalline cellulose, polydextrose, polyethylene glycol, povidone, sodium stearyl fumarate, titanium dioxide, triacetin, triethyl citrate, vinyl acetate copolymer. 

The USP dissolution test is pending.
Provided herein are methods of detecting a biological substance in a sample. Detection is based on the formation of aggregates. The disclosed compositions include label particles and/or aggregate particles. The label particles and the aggregate particles may each comprise a receptor bound to the particle. The receptor may be directly attached to the particle, or indirectly attached to the particle through a linker. One detection method may be visual and another detection method may include advanced quantification of the aggregates formed.
PROBLEM TO BE SOLVED: To obtain a bath agent which is excellent in the effect of preventing harshness of the skin after bathing and rendering the skin smooth, and can impart comfort in use by incorporating a hydrophilic polyether polymer having specified structural units. SOLUTION: This bath agent compsn. contains a hydrophilic polyether polymer, with a wt. average mol.wt. of 500 to 500,000, comprising structural units represented by formula I (wherein R<1> and R<2> represent each a 1-20C alkyl group which may contain a hydroxyl group; and Y represents a 1-20C divalent satd. hydrocarbon group which may contain a hydroxyl group), the hydrophilic polyether polymer being contained in an amt. of 0.1 to 80 pts.wt. based on 100 pts.wt. bath agent compsn. In use, the bath agent compsn. is introduced into bathwater at the time of bathing so that the concentration of the hydrophilic polyether polymer in the bathwater is 0.5 to 100,000 ppm.  Polymers represented by formula II (wherein (n) is 50 to 200) and copolymers comprising structural units represented by formula III (wherein (p) is 2; (q) is 1; and (r) is 1) and structural units represented by formulae IV, V, and VI (wherein (p) is 2; (q) is 1; and (s) is 1) may be exemplified as some examples of pref. polymers.
The present invention relates to a functional cosmetic composition containing, as active ingredients, extracts of bergamot, Lonicera japonica Thunberg, Coix lachryma-jobi var. mayuen, and wheat buds for anti-wrinkling, skin whitening, and promotion of damaged skin recovery. The cosmetic composition for anti-wrinkling according to the present invention can be useful as a cosmetic composition for skin whitening since respective ingredients exhibit an anti-wrinkling effect and an excellent skin whitening effect when used alone. In addition, the composition exhibits an excellent effect of promoting the recovery of skin tissue damage caused by chemical materials, thereby providing a superior cosmetic composition for damaged skin tissue recovery. In addition, the composition can have superior effects when the mixed extracts are mixed with a Portulaca oleracea extract, an Atractylodis rhizoma extract, a wild chrysanthemum extract, a Ledebouriella seseloides extract, an Eclipta prostrate extract, a Paeonia japonica extract, and the like. The composition exhibits various functions, and thus can be used as a complex functional composition.
ERAS-601 will be administered in sequential ascending doses with cetuximab to study participants with advanced metastatic solid tumors until unacceptable toxicity, disease progression or withdrawal of consent. Once the combination therapy recommended dose has been determined, this will be administered to study participants with HPV negative advanced or metastatic head and neck squamous cell carcinoma (HNSCC) or colorectal cancer (CRC).
PURPOSE: The radiographic rectus width to hernia width ratio (RDR) has been shown to predict ability to close fascial defect without additional myofascial release in open Rives-Stoppa abdominal wall reconstruction (AWR), but it has not been studied in robotic AWR. We aimed to examine various CT measurements to determine their usability in predicting the need for transversus abdominis release (TAR) in robotic AWR.
METHODS: We performed a single-center retrospective review of 137 patients with midline ventral hernias over a 5-year period who underwent elective robotic retrorectus AWR. We excluded patients with M1 or M5 hernias, lateral/flank hernias, and hybrid repairs. The CT measurements included hernia width (HW), hernia width/abdominal width ratio (HW/AW), and RDR. Univariate, multivariate and area under the curve (AUC) analyses were performed.
RESULTS: 58/137 patients required TAR (32 unilateral, 26 bilateral). Patients undergoing TAR had a significantly higher average HW and HW/AW and lower RDR. Multivariate analysis revealed that prior hernia repair was independently associated with need for TAR (p = 0.03). ROC analysis and AUC values showed acceptable diagnostic ability of HW, HW/AW and RDR in predicting need for TAR. Cutoffs of RDR ≤ 2, HW/AW > 0.3, and HW > 10 cm yielded high specificity in determining need for any TAR (97.5% vs. 96.2% vs. 92.4%) or bilateral TAR (95.5% vs. 94.6% vs. 92.8%).
CONCLUSION: History of prior hernia repair was a risk factor for robotic TAR. CT measurements have some predictive value in determining need for TAR in robotic AWR. Further prospective analysis is needed in this patient population.
The increasing prevalence of non-communicable chronic diseases on a global, regional, and local scale demonstrates the extensive impact of these diseases, which now account for 70% of all worldwide deaths and affect a diverse population outside affluent places. The purpose of this study was to assess the prevalence and associated factors of non-communicable chronic diseases among academics at Mutah University in Jordan, while also taking into account the global trend of non-communicable diseases impacting different demographics. In a cross-sectional study, the majority of faculty members completed a questionnaire that included demographic information and prevalence of chronic diseases. The most prevalent conditions detected were hypertension (19.6%), diabetes mellitus (17.5%), rheumatoid arthritis (14.2%), heart disease (12.6%), and respiratory disorders (11.3%). Specifically, smoking and being overweight are underlined as significant risk factors, particularly among male respondents. These findings highlight the need of implementing health promotion programs in educational academic institutions, with an emphasis on fostering healthy dietary habits and encouraging physical activity.
This disclosure relates to internal ribosome entry site (IRES) elements that are capable of effectuating expression of a desired polynucleotide even in the absence of a 5' cap structure. The disclosure also provides polynucleotides (e.g., RNA molecules, such as circular or linear RNA molecules) containing such IRES elements. In some embodiments of the disclosure, the IRES element contains one or more nucleic acid segments that are enriched in uridine nucleosides or modified uridine nucleosides, such as 1-methylpseudouridine nucleosides. In some embodiments, the IRES element contains one or more nucleic acid segments that feature a plurality of contiguous uridine nucleosides or modified uridine nucleosides (e.g., 1-methylpseudouridine nucleosides). In some embodiments, the IRES elements described herein can recruit ribosomes and/or translation initiation factors by, e.g., binding to ribosomes, hybridizing to the ribosomal RNA of a ribosome, or binding to translation initiation factors. The polynucleotides (e.g., circular or linear RNA molecules) of the disclosure may be used to express a desired polypeptide in a subject, such as a subject having a disease or condition associated with a deficiency in the corresponding endogenous polypeptide.
Systems and methods for aiding individuals to complete tasks of daily living are provided. The situationally aware system comprises a controller, sensors, and effectors. The controller may include a program that describes a sequence of steps the user should perform to accomplish the task. In response to the information from the sensors and the user's compliance with the steps of the sequence, the controller instructs the effector(s) to relay at least one instructional cue to the user to aid in the performance of the task. The instructional cue may range from a simple blinking light, to detailed audio and/or visual instructions, to relaying a reward for the completion of the task. The instructional cue may also instruct the user to refrain from performing a task. The system is programmable, configurable, and may interface to the Internet.
Insomnia affects approximately one-third of older Americans. More than half of all people aged 65 and older experience sleep problems. The prevalence of insomnia and other sleep disorders is not a natural part of aging but is high in older adults because of a variety of factors common in late life. One of those factors may be a deficient magnesium status. There is a close association between sleep architecture, especially slow wave sleep, and activity in the glutamatergic and gamma-aminobutyric acid (GABA) system. Because magnesium is a natural N-methyl-D-aspartate (NMDA)antagonist and GABA agonist, magnesium apparently plays a key role in the regulation of sleep. Such a role is supported by supplementation, correlation, and animal studies showing that magnesium intake or status affects sleep organization.
The present invention relates to a novel class of anti-cancer compounds which selectively target androgen receptor (AR)-expressing cancer cells, such as prostate cancer cells and breast cancer cells. These agents comprise an androgen receptor (AR) binding moiety, which selectively targets the compounds to (AR)-expressing cancer cells, and a cytotoxic alkylating moiety, such as a nitrogen mustard moiety. The inherent high density expression of the androgen receptor in certain cancers, such as prostate cancer and breast cancer, is thus used as a tool to selectively increase the intracellular concentration of cytotoxic compounds, such as alkylating agents, e.g. DNA alkylating agents, by selectively targeting the agents to the AR-expressing cancer cells. These agents, either alone or in a composition, are thus useful for treating, delaying the progression of, treating the recurrence of, suppressing, inhibiting or reducing the incidence of cancers characterized by the presence of AR-expressing cells, such as prostate cancer. Accordingly, the present invention provides (a) methods of selectively killing an (AR)-expressing cancer cell; (b) methods of inducing apoptosis in an (AR)-expressing cancer cell; (c) methods of treating a cancer characterized by the presence of AR-expressing cells in a subject; (d) methods of delaying the progression of a cancer characterized by the presence of AR-expressing cells in a subject; (e) methods of treating the recurrence of a cancer characterized by the presence of AR-expressing cells in a subject; (f) methods of suppressing, inhibiting or reducing the incidence of a cancer characterized by the presence of AR-expressing cells in a subject; and (g) methods of treating metastasis of a cancer characterized by the presence of AR-expressing cells in a subject; by administering to the subject or by contacting the cancer cells with a compound comprising an androgen receptor ligand moiety and an alkylating moiety, such as the novel compounds described herein.
Initially the aim is to recruit 5 clinicians to play the existing MoM game in a controlled environment. The goal is to congregate their collective feedback about the existing game as well as additional features that needs to be implemented to comprise Exposure Therapy to treat OCD with cleanliness. In addition, a feasibility analysis will be conducted to the proposed gameplay described in section 3.1.1. With these assessments, implementation process will be initiated.